SELECT trial information

The double-blinded SELECT cardiovascular outcomes trial compared subcutaneous once-weekly semaglutide 2.4 mg with placebo as an adjunct to standard of care for prevention of major adverse cardiovascular (MACE) events over a period of up to 5 years. Read more about its background, methodology, results, and more.

resources
SELECT trial resources
 
Preview
SELECT Trial PDF

Trial Rationale

Trial Rationale for the SELECT trial

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
SELECT trial resources
 
Preview
SELECT Trial PDF

Trial Design

Trial Design for the SELECT trial

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
SELECT trial resources
 
Preview
SELECT Trial PDF

Trial Objectives

Trial Objectives for the SELECT trial

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
SELECT trial resources
 
Preview
SELECT Trial PDF

Baseline Characteristics

Baseline Characteristics for the SELECT trial

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close

Semaglutide s.c. 2.4 mg OW is not indicated for MACE risk reduction. Safety and efficacy are not established for this use under investigation. Semaglutide s.c. 2.4 mg OW is FDA-approved for chronic weight management in adults with obesity (BMI > 30), or overweight (excess weight) (BMI > 27) who also have weight-related medical problems, used with a reduced-calorie meal plan and increased physical activity. Semaglutide s.c. 2.4 mg OW is also indicated for use in patients aged 12 years and older with an initial BMI at or above the 95th percentile for age and sex.  Please see the full prescribing information for Semaglutide s.c. 2.4 mg OW here. Novo Nordisk does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.

Featured Insights and Resources

SELECT trial resources
 
Preview
SELECT Trial PDF

Trial Rationale

Trial Rationale for the SELECT trial

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
Novo Nordisk® Scientific Exchange logo

Scientific Exchange is a trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.

This medical content was developed independently by a third party via an educational grant. This material is copyright protected and is provided here with permission for educational and informational purposes only and is not certified for continuing education credits.

Continue

You are now leaving the Novo Nordisk Scientific Exchange website.

Our Privacy Policy applies only to this and other websites maintained by Novo Nordisk. Links are provided as a public service and for informational purposes only. No endorsement is made or implied. Click "Continue" to leave this site.

Continue

GATED INTERSTITAL  

You are now leaving the Novo Nordisk Scientific Exchange website.

Our Privacy Policy applies only to this and other websites maintained by Novo Nordisk. Links are provided as a public service and for informational purposes only. No endorsement is made or implied. Click "Continue" to leave this site.

ACCESS DENIED

Our Privacy Policy applies only to this and other websites maintained by Novo Nordisk. Links are provided as a public service and for informational purposes only. No endorsement is made or implied. Click "Continue" to leave this site.